GLP-1s broke the system

GLP-1s broke the system

The explosive rise of GLP-1 medications—such as Mounjaro, Ozempic, and Wegovy—has ignited more than just headlines. It has fundamentally shifted how Americans access and pay for medications, driving innovation in affordability models, and fueling a dramatic increase in direct-to-consumer (DTC) healthcare platforms. Originally approved for type 2 diabetes, GLP-1s have surged in popularity due to their effectiveness in treating obesity and other c…

5 End of Summer Broker Alerts: Subsidies, GLP-1s, Penalties & More

This summer has flown by and the kids are back in school. As Q4 and open enrollment are upon us, these are some of the summer trends that brokers can’t ignore that you may have missed and why they matter. Between the ACA subsidy cliff, rising 2026 employer health costs, newly indexed ESRP penalties, a GLP-1–driven pharmacy spend squeeze, and a growing price-transparency crackdown, the ground is shifting fast for brokers. Below are five developme…